Skip to content

The effect and mechanism of fecal microbiota transplantation on immune regulation of gut-liver axis in patients with liver failure.

The effect and mechanism of fecal microbiota transplantation on gut-liver axis immune regulation and Treg / Th17 cell balance in patients with acute-on-chronic liver failure.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034219
Enrollment
Unknown
Registered
2020-06-28
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver failure

Interventions

experimental group:Fecal microbiota transplantation, once in 5 days, 4 times in total

Sponsors

Ningbo Medical Center Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients willing to sign informed consent; 2. Patients aged 18-65; 3. According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL = 10 × ULN or the daily rise = 17.1 µ mol / L; there was bleeding, PTA = 40% (or INR = 1.5)

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc; 2. Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc; 3. Patients with liver cancer, lung cancer, lymphoma and other malignant tumors; 4. Patients taking anticoagulants, mental diseases and immune diseases for a long time; 5. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Liver function;Kidney function;Prothrombin time;Model for end-stage liver disease score;blood routine examination;Radiography;

Countries

China

Contacts

Public ContactXu Lanman

Ningbo Medical Center Lihuili Hospital

13587646315@163.com+86 13587646315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026